ArticleCase reports in endocrinology2020
Parathyroid Carcinoma in the Setting of Tertiary Hyperparathyroidism: Case Report and Review of the Literature.
Article in Case reports in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- The Complementary Roles ofMolecular imaging and radionuclide therapy · 2026Article
- Diffuse skeletal [Asia Oceania journal of nuclear medicine & biology · 2026Article
- Cohort review of patients with parathyroid cancer in End Stage Renal Disease (ESRD).Langenbeck's archives of surgery · 2024Review
- Coincidence or Causality: Parathyroid Carcinoma in Chronic Kidney Disease-Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2024Article
- Tertiary hyperparathyroidism masking an atypical parathyroid tumor.Clinical case reports · 2024Article
- Unveiling potential drug targets for hyperparathyroidism through genetic insights via Mendelian randomization and colocalization analyses.Scientific reports · 2024Article
- Left parathyroid carcinoma with secondary hyperparathyroidism: a case report.BMC endocrine disorders · 2023Article
- Case report: Sagliker syndrome in the patient with recurrent tertiary hyperparathyroidism due to intrathyroidal parathyroid carcinoma.Frontiers in endocrinology · 2023Article
- Overview of the 2022 WHO Classification of Parathyroid Tumors.Endocrine pathology · 2022Review
- Advances in the treatment of secondary and tertiary hyperparathyroidism.Frontiers in endocrinology · 2022Review
- A Bibliometric Analysis of the Landscape of Parathyroid Carcinoma Research Based on the PubMed (2000-2021).Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParathyroid carcinoma is one of the rarest cancers in normal population, and it is extremely uncommon in the setting of tertiary hyperparathyroidism. Indeed, only 24 cases have been reported in the literature.
conclusionTo date, radical surgery represents the mainstay of treatment, with a five- and ten-year survival rates overall acceptable.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.